<DOC>
	<DOC>NCT03018028</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic control in Japanese subjects with type 2 diabetes mellitus</brief_summary>
	<brief_title>Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtained before any trialrelated activities. Trialrelated activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial Japanese male or female, age above or equal to 20 years at the time of signing informed consent Diagnosed with type 2 diabetes mellitus for at least 30 days prior to day of screening HbA1c 6.5%−9.5% (48−80 mmol/mol) (both inclusive) for subjects treated with oral antidiabetic drug as monotherapy and 7.0%−10.0% (53−86 mmol/mol) (both inclusive) for subjects treated with diet and exercise therapy alone Treatment for at least 30 days prior to day of screening with; stable daily dose of oral antidiabetic drug as monotherapy (allowed oral antidiabetic drugs are: metformin, sulphonylurea, glinide, αglucosidase inhibitor, dipeptidyl peptidase4 inhibitor and sodiumglucose cotransporter2 inhibitor) at a halfmaximum approved dose or below according to Japanese labelling in addition to diet and exercise therapy. or diet and exercise therapy alone Female who is pregnant, breastfeeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method. Adequate contraceptive measures are abstinence (not having sex), diaphragm, condom (by the partner), intrauterine device, sponge, spermicide or oral contraceptives Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol Family or personal history of multiple endocrine neoplasia type 2 (MEN 2) or medullary thyroid carcinoma (MTC) History of pancreatitis (acute or chronic) History of major surgical procedures involving the stomach and potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) Any of the following: myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening and randomisation Subject presently classified as being in New York Heart Association (NYHA) Class IV Planned coronary, carotid or peripheral artery revascularisation known on the day of screening Subjects with alanine aminotransferase (ALT) above 2.5 x upper normal limit (UNL) Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) below 30 mL/min/1.73 m^2 as per Chronic Kidney Disease Epidemiology Collaboration formula (CKDEPI) Treatment with onceweekly glucagonlike peptide1 receptor agonist (GLP1 RA), once weekly dipeptidyl peptidase4 (DPP4) inhibitor or thiazolidinedione in a period of 90 days before the day of screening Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 60 days before the day of screening. An exception is shortterm insulin treatment for acute illness for a total of below or equal to 14 days Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within 90 days prior to randomisation History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and insitu carcinomas) Initiation of antidiabetic medication between the day of screening and the day of randomisation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>